HUMAN C1 INHIBITOR IN HEREDITARY AND ACQUIRED ANGIOEDEMA

人类 C1 抑制剂治疗遗传性和获得性血管性水肿

• 批准号: 6441971
• 负责人: RAIF SALIM GEHA
• 金额: $ 2.88万
• 依托单位: BOSTON CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-12-01 至 2001-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6441971
• 关键词: cardiovascular disorder chemotherapy; clinical research; clinical trials; complement inhibitors; drug screening /evaluation; hereditary angioneurotic edema; human subject; human therapy evaluation; immunotherapy; urticaria

Open-label study of C1 INH-IMMUNO in the treatment of Hereditary Angioedema (HAE). HAE is a condition in which acute, recurrent episodes of well circumscribed, nonpitting, subepithelial edema primarily involving the extremities, face, abdomen, and larynx. HAE is characterized by a marked decrease in functional C1 inhibitor. This study attempts to control the symptoms of HAE by administering C1 inhibitor. The C1 inhibitor is effective therapy for the treatment of attacks of HAE with no adverse reactions.

C1INH免疫治疗遗传性血管性水肿的开放标记研究HAE是一种急性、反复发作的局限性良好的非凹陷性上皮下水肿，主要累及四肢、面部、腹部和喉部。HAE的特征是功能性C1抑制物显著减少。本研究试图通过给予C1抑制剂来控制HAE的症状。C1抑制剂是治疗HAE发作的有效疗法，且无不良反应。